Adipose-Derived Stem Cell Exosomes as a Novel Anti-Inflammatory Agent and the Current Therapeutic Targets for Rheumatoid Arthritis

Ting-Hui Chang 1, Chien-Sheng Wu 1, Shih-Hwa Chiou 2,3,4, Chih-Hung Chang 5,6,* and Hsiu-Jung Liao 7,*

1 Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan; ahui815@yahoo.com.tw (T.-H.C.); wucs.tw@gmail.com (C.-S.W.)
2 Department of Medical Research, Taipei Veterans General Hospital, Taipei 100136, Taiwan; shchiou@vghtpe.gov.tw
3 Genomic Research Center, Academia Sinica, Taipei 115021, Taiwan
4 Institute of Pharmacology, National Yang-Ming Chiao-Tung University, Taipei 30093, Taiwan
5 Department of Orthopedic Surgery, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan
6 Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan City 320315, Taiwan
7 Department of Medical Research, Far Eastern Memorial Hospital, New Taipei City 220216, Taiwan
* Correspondence: cch@mail.femh.org.tw (C.-H.C.); liaohsiujung@gmail.com (H.-J.L.)

Abstract: Patients with rheumatoid arthritis (RA), a chronic inflammatory joint disorder, may not respond adequately to current RA treatments. Mesenchymal stem cells (MSCs) elicit several immunomodulatory and anti-inflammatory effects and, thus, have therapeutic potential. Specifically, adipose-derived stem cell (ADSC)-based RA therapy may have considerable potency in modulating the immune response, and human adipose tissue is abundant and easy to obtain. Paracrine factors, such as exosomes (Exos), contribute to ADSCs’ immunomodulatory function. ADSC-Exo-based treatment can reproduce ADSCs’ immunomodulatory function and overcome the limitations of traditional cell therapy. ADSC-Exos combined with current drug therapies may provide improved therapeutic effects. Using ADSC-Exos, instead of ADSCs, to treat RA may be a promising cell-free treatment strategy. This review summarizes the current knowledge of medical therapies, ADSC-based therapy, and ADSC-Exos for RA and discusses the anti-inflammatory properties of ADSCs and ADSC-Exos. Finally, this review highlights the expanding role and potential immunomodulatory activity of ADSC-Exos in patients with RA.

Keywords: adipose-derived stem cell; rheumatoid arthritis; exosome; anti-inflammation

1. Introduction

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation, which results in cartilage erosion and bone loss [1–6]. The mechanism underlying its development is highly complex because it involves an interplay between genetic and environmental factors [7]. The infiltration of inflammatory cells is a pathologic feature of RA, followed by synovial membrane hyperplasia and osteoclast over-activation [8]. Many studies have indicated that various types of immune cells, including T cells, macrophages, and B cells, are responsible for RA pathogenesis [9–13].

The main mechanism of action of the currently available RA therapeutics is inhibiting inflammation, to reduce joint damage and prevent bone loss. However, the conventional disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) used for RA treatment are nonspecific. Therefore, they non-selectively affect physiological pathways other than the immune response, increasing the risk of adverse events in the long term [14–16]. Several types of biologic DMARDs (bDMARDs) and small-molecule compounds exist, such as Janus kinase (JAK) inhibitors, compounds that target specific immune cells, cytokines, and compounds that modulate...
cytokine pathways [17,18]. In contrast to NSAIDs or glucocorticoids, which temporarily alleviate pain and inflammation, DMARDs delay RA progression [19]. DMARD treatment is effective in most patients with RA; however, 20%–30% of patients with RA do not respond to the treatment, or they experience major side effects from it. Moreover, biologics are not recommended for patients with compromised immune systems or infections because their use can increase the risk of infection [20].

Adipose-derived stem cells (ADSCs), which have strong immunomodulatory properties, can be readily isolated from adipose tissue and cultured in vitro [21–23]. Human ADSCs have been shown to be a promising therapeutic agent for RA [24]. Furthermore, they have a unique immunological profile, which enables adoptive transfer in allogeneic recipients with minimal risk of rejection. Therefore, ADSCs may have great therapeutic potential in patients with RA. As such, the establishment of cell banks using ADSCs from relatively few donors is warranted to facilitate widespread use among unrelated allogeneic recipients with RA [25–27]. It is important to note that patients with RA must receive medical treatments that may interfere with the outcomes of ADSC-based therapy. Therefore, the use of allogeneic ADSC-derived exosomes (Exos) may be easier than that of autologous mesenchymal stem cells (MSCs) or MSC-Exos in patients with RA.

Here, we comprehensively review the conventional and innovational treatment approaches used for RA treatment, such as MSC-Exo-based therapy, to understand the interplay between MSC-Exos and the innate and adaptive immune systems. Moreover, we discuss the biological characteristics of ADSC-Exos and review their experimentally verified RA therapeutic outcomes.

2. Current Therapy for RA

The currently available therapeutic drugs used for RA treatment can be classified into nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, nonbiologic or conventional synthetic DMARDs (csDMARDs), biologic agents or bDMARDs, and targeted synthetic DMARDs (tsDMARDs) [28]. NSAIDs are most frequently used to mitigate pain. In addition, various combinations of corticosteroids may be administered to leverage their potent anti-inflammatory effects. Corticosteroids are potent anti-inflammatory drugs that modulate gene expressions by binding to glucocorticoid receptors to exert anti-inflammatory and immunosuppressive effects. However, their side effects include nausea, abdominal pain, osteoporosis, and metabolic disorders, which often worsen the quality of life of patients with RA [29].

csDMARDs are relatively safe and efficacious. Commonly used conventional DMARDs include methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine [30]. In patients with definite RA, treatment with DMARDs is started as soon as the RA diagnosis is made. However, their use may be discontinued in the case of toxicity or loss of effect. In patients with well-controlled RA under csDMARD treatment, the discontinuation of the treatment increases the risk of flares. Patients started on DMARDs in the early stages of RA are likely to also require them in the later stages of the disease [31].

bDMARDs and tsDMARDs are added to RA treatment in patients unresponsive to tsDMARDs. bDMARDs (e.g., adalimumab, infliximab, certolizumab, and tocilizumab) are monoclonal antibodies that particularly target tumor necrosis factor (TNF)-α and interleukin (IL)-6 [32]. tsDMARDs typically target specific cytokine pathways; for instance, tofacitinib, baricitinib, filgotinib, upadacitinib, and decernotinib specifically target Janus kinase [33].

2.1. NSAIDs and Glucocorticoids

NSAIDs are ubiquitously used in rheumatology due to their effectiveness as anti-inflammatory and analgesic agents [34–36]. Although they differ widely in terms of chemical class, all NSAIDs can block prostaglandin (PG) production by inhibiting the enzyme PGH synthase, also called cyclooxygenase (COX). COX occurs in two isoforms, COX-1 and COX-2, which differ in regulations and tissue distribution and perform different bio-
logical functions: COX-1, expressed under basal conditions, is involved in PG production under homeostatic functions [37], whereas COX-2 expression increases during inflammation and other pathologic situations. The inhibition of COX-2 expression by NSAIDs blocks PG production at sites of inflammation or other forms of tissue damages [35]. However, due to low target specificity, COX-1 inhibition by NSAIDs in other specific tissues, most notably platelets and the gastroduodenal mucosa, can lead to common adverse effects such as bleeding and gastrointestinal ulceration [38]. Chronic systemic inflammation and cardiovascular risk factors are the main determinants of increased cardiovascular risk in patients with RA. However, NSAIDs may reduce the cardiovascular risk in patients with RA who frequently use them [39].

Glucocorticoids are anti-inflammatories with an essential role in RA management. Their clinical and structural efficacy has been widely acknowledged [40]. Most studies have evaluated their efficacy in bridging therapy, in combination with csDMARDs. However, most of the relevant studies have mainly focused on patients with early RA; there is a paucity of corresponding data for late-stage RA. Nevertheless, glucocorticoids may aid in controlling flares among patients with RA [41,42]. Adding glucocorticoids to bDMARDs and nonbiologic DMARDs most likely presents no or few undesirable effects, because most DMARDs have a fast onset of action [43,44]. Glucocorticoids are also inexpensive, and in combination with nonbiologic DMARDs, they may reduce or delay the need for the long-term use of biologic and nonbiologic DMARDs [45]. By contrast, glucocorticoid monotherapy is not acceptable because of the associated adverse effects [46]. Long-term, high-dose glucocorticoid use can lead to serious adverse effects, such as immunosuppression, osteoporosis, and metabolic disorders [47].

2.2. csDMARDs

csDMARDs, the cornerstone for RA management, can reduce pain and disability in patients with RA. However, all of the currently available csDMARDs have limited efficacy and some toxicity-related issues. Consequently, the interest in developing safe and effective treatment modalities for RA is growing. DMARDs are the immunosuppressive and immunomodulatory agents [48]. The most widely used csDMARDs include methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. Each DMARD has a unique mechanism of actions, but they all ultimately interfere with critical pathways in the inflammatory cascades. For example, methotrexate stimulates the releases of adenosine from fibroblasts, reduces neutrophil adhesion, inhibits leukotriene B4 synthesis by neutrophils, inhibits local IL-1 production, reduces IL-6 and IL-8 levels, suppresses cell-mediated immunity, and inhibits synovial collagenase gene expression [49]. Other medications in this class inhibit lymphocyte proliferation or cause lymphocyte dysfunction. For example, leflunomide suppresses dihydroorotate dehydrogenase, resulting in the inhibition of pyrimidine synthesis, thereby blocking lymphocyte proliferation or [50]. Sulfasalazine has anti-inflammatory effects and prevents oxidative, nitrative, and nitrosative damages [51]. By contrast, hydroxychloroquine is an extremely mild immunomodulatory agent that blocks the intracellular toll-like receptor TLR9 [52].

2.3. bDMARDs

Numerous biological agents targeting various established cytokines or cellular subsets of the immune system have been developed. These agents demonstrate high efficacy for RA treatment; they can alleviate pain, improve quality of life, and considerably prevent structural damage. However, approximately 30%-50% of patients with RA do not demonstrate appropriate clinical responses to these drugs [53]. bDMARDs are highly specific and target a particular immune pathway. Some of these drugs are monoclonal, chimeric humanized fusion antibodies. Newer bDMARDs, with various modes of action, can be administered to RA patients who are unresponsive to TNF-inhibitor treatment [54]. For instance, abatacept (ABT, which interrupts the costimulation molecule signal between T and B cells) [55], rituximab (RTX, which targets CD20+ B cells) [56], and tocilizumab (TCZ,
which is an IL-6 receptor (IL-6R) antagonist) [57] have demonstrated high treatment efficacy in patients with active RA, particularly in those with inadequate responses to TNF-inhibitor treatment [58].

2.4. Small-Molecule Compounds or tsDMARDs

Tofacitinib, the first FDA-approved tsDMARD, functions by inhibiting JAKs [59,60]. Other agents with similar modes of action are also available. However, these agents are generally recommended only to patients unresponsive to methotrexate or other conventional nonbiologic DMARDs or bDMARDs. All the JAK inhibitors used for RA treatment are administered orally; therefore, patients may prefer these agents over bDMARDs, which can only be administered intravenously or subcutaneously [61]. Small-molecule inhibitors have shorter half-lives than bDMARDs, and they need to be taken either once or twice a day. In general, small-molecule inhibitors are as small as \( \leq 500 \) Da in size, much smaller than bDMARDs, which tend to be \( >1000 \) Da. tsDMARDs inhibit the intracellular signaling pathways of proinflammatory cytokines, in contrast to the mechanism of action of bDMARDs, which only block specific extracellular molecules [62,63]. Figure 1 summarizes the currently available bDMARDs and tsDMARDs for treating RA.

![Figure 1. Mechanism of the currently available drugs for RA treatment.](image)

3. Generation of ADSCs and Their Therapeutic Application in RA

A large amount of adipose tissue can be obtained from the infrapatellar fat pads located in the extrasynovial area of the knee’s anterior compartment (Figure 2A) and subcutaneous fat (Figure 2B) removed through liposuction. ADSCs can exert immunosuppressive effects on both innate and adaptive immune cells, and they have been proposed as a therapeutic agent for autoimmune disease [64]. For instance, ADSCs have been used to modulate myeloid cells' and lymphocytes' differentiation toward their immunosuppressive phenotypes. The targeted immune cells include monocytes [65], macrophages [66], dendritic cells [67], and regulatory T (Treg) cells [68,69]. Furthermore, MSCs inhibit T and B cells' proliferation and function [70–72].

MSCs derived from adipose tissue have therefore attracted considerable attention. Recent studies have evaluated the MSC dose tolerance, compared the efficiency of ADSCs and current RA drug treatments, investigated ADSCs' capacity to alleviate or prevent the inflammation associated with RA and control other immune responses associated with RA propagation, and evaluated the safety of allogeneic ADSC transplantation [26,73]. The
related clinical trials reported to date have consistently indicated that ADSCs are safe and effective in RA-related transplantation and treatment [74]. A phase Ib/IIa clinical trial showed that intravenously administered allogeneic ADSCs were safe and well-tolerated in patients with refractory RA, without dose-related toxicity for the dose ranges and exposure times studied [75]. In particular, three miRNAs—miR-26b-5p, miR-487b-3p, and miR-495-3p—were confirmed to be significantly upregulated in the ADSC-responder group compared to the ADSC-nonresponder group [25]. These miRNAs may represent novel candidate biomarkers associated with RA patients’ responses to ADSCs.

Figure 2. Infrapatellar fat pads (IPFPs) and subcutaneous fat pads, which are primary sources of ADSCs for RA treatment. (A) The IPFP is deep into the patella and locates the space between the patellar tendon, femoral condyle, and tibial plateau and plays a crucial biomechanical role within the knee. IPFP also acts as a reservoir of ADSCs. (B) The subcutaneous fat pad represents an emerging alternative source of ADSCs and can be obtained from abundant adipose tissue by a minimally invasive procedure.

To enhance the understanding of the mechanisms underlying MSC-based RA treatment, the details of large-scale clinical trials with mandatory follow-up protocols reported to date are summarized in Table 1.

Table 1. Potential of ADSCs and ADSC-Exos for the alleviation of the RA-related inflammation noted in clinical studies.

| Cell Source                              | Treatment Conditions      | Outcome                                                                 | Number of Patients | Reference |
|------------------------------------------|--------------------------|------------------------------------------------------------------------|--------------------|-----------|
| Allogeneic subcutaneous adipose tissue   | (3–12) × 10^6 cells/kg, i.v. | Treatment was generally well-tolerated, without dose-related toxicity in the dose range and time | 46 (RA)            | [75]      |
| Autologous subcutaneous adipose tissue  | (1.5–3.5) × 10^6 ADSCs/kg, s.c. | Pain VAS and KWOMAC decreased, and walking improved                     | 3 (RA)             | [76]      |
| Allogeneic subcutaneous adipose tissue   | Expanded allogeneic ADSCs in refractory RA, i.v. | Three miRNAs, namely, miR-26b-5p, miR-487b-3p, and miR-495-3p, were significantly upregulated in the responder group (reduced MRI score) compared to the nonresponder group | 14 (RA)            | [25]      |
3.1. Clinical Studies of ADSCs in Patients with RA

Some patients with RA require long-term glucocorticoid treatment to control their RA symptoms. However, a Korean research team, for the first time, reported the outcomes of ADSC-based therapy and the subsequent discontinuation of glucocorticoid use in humans [76]. In the study, which included three patients with RA, ADSCs were extracted from autologous adipose tissues, cultured, expanded, and administered to patients intravenously or through intra-articular injection. The first patient, who received two intravenous injections of $3 \times 10^8$ ADSCs, had improved pain visual analog scale (VAS) scores, which decreased from 10 to 2–3, and improved Korean Western Ontario and McMaster Universities arthritis index scores, which decreased from 73 to 28. The second patient received an intravenous injection of $2 \times 10^8$ ADSCs and an intra-articular injection of $1 \times 10^8$ ADSCs, followed by an additional intravenous injection of $3.5 \times 10^8$ ADSCs and an intra-articular injection of $1.5 \times 10^8$ ADSCs. This patient previously had difficulty walking, but after treatment, they could walk easily and stopped taking steroids. Finally, the third patient received four intravenous injections of $2 \times 10^8$ ADSCs; after treatment, this patient could also walk easily and stopped taking steroids. This study indicates the potential efficacy and safety of autologous ADSCs in patients with RA. However, the limitations of the study were the small sample size, absence of objective indices with which to evaluate the response (e.g., the ACR response or DAS28 score), and short follow-up duration (3–13 months) [24,77,78].

The inflammatory environment of the RA synovium may trigger the immunomodulatory potential of ADSCs. Inflammatory synovial fluid from patients with RA can modulate ADSCs’ responses to induce Treg cells and modulate the phenotype of M2 macrophages. Proinflammatory synovial fluid maintains ADSC proliferation and upregulates the expression of the genes involved in immunomodulatory potential through a TNF- and NF-κB-dependent mechanism [79]. Furthermore, in a previous study, ADSCs exposed to proinflammatory synovial fluid were more effective in inducing Treg cells and inhibiting proinflammatory macrophages than those exposed to control synovial fluid, suggesting that maintaining ADSCs’ anti-inflammatory properties is essential for maximizing their effect in the local joint inflammatory environment.

The anti-inflammatory capacities of ADSCs from infrapatellar fat pads (IPFPs) and those from subcutaneous (SC) adipose tissues are the same. Skalska et al. reported that IPFP-MSCs and SC-MSCs obtained from patients with RA possessed similar immunomodulatory properties, despite their different localizations and the distinct cytokine milieus of the tissues of origin. Moreover, ADSCs derived from RA adipose tissues are not strongly immunosuppressive in vitro, and they may contribute to RA pathogenesis because of the enhancement of IL-17A secretion [74]. In their in vitro study, Skalska et al. reported that RA-ADSCs and osteoarthritis-ADSCs (OA-ADSCs) did not suppress the expression of activation markers in T cells or trigger Treg-cell expansion. Moreover, IPFP-MSCs from patients with RA and OA demonstrated comparable functions in vitro. However, their immunosuppressive activity appeared to be relatively impaired in patients with RA [26]. Table 2 demonstrates the potential of ADSCs and ADSC-Exos for alleviating the RA-related inflammation noted in vitro studies.
Table 2. Potential of ADSCs and ADSC-Exos for the alleviation of the RA-related inflammation noted in in vitro studies.

| In Vitro Study                                      | Cell Source                                  | Treatment Conditions                                                                 | Outcome                                                                                                                                  | Number of Patients | Reference |
|----------------------------------------------------|----------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------|
|                                                    | Subcutaneous adipose tissue                  | ADSCs first treated with SF and ADSC proliferation followed by gene expression of immunomodulatory factors | Conditioning ADSCs with proinflammatory RASF enhanced their ability to induce Treg cells and inhibited the proinflammatory markers CD40 and CD80 in activated macrophages | 8 (RA)            | [79]      |
|                                                    | Subcutaneous adipose tissue                  | ADSC–PBMCs cocultured with PMA treatment                                             | ADSCs greatly upregulated Th2- and Treg-cell transcription factors (i.e., GATA3 and Foxp3) and downregulated Th1 and Th17 transcription factors (i.e., T-bet and RORγt) | 14 (RA)            | [80]      |
|                                                    | Infrapatellar fat pad or subcutaneous adipose tissues | PBMCs stimulated with PHA cultured alone or in the presence of naïve or TNF/IFNγ-pretreated ASCs isolated from infrapatellar fat pads or subcutaneous adipose tissues | IPFP-MSCs and SC-MSCs obtained from patients with RA had similar immunomodulatory properties despite the different localization and distinct cytokine milieu of the tissues of origin | 8 (RA)            | [74]      |
|                                                    | Infrapatellar fat pad                        | PBMCs from healthy donors cocultured with ADSCs from patients                        | The immunosuppressive properties of RA-ADSCs and OA-ADSCs were impaired                                                              | 29 (RA) 12 (OA)    | [26]      |
|                                                    | Subcutaneous adipose tissue                  | ADSCs from healthy donor cultured with collagen-reactive RA human T cells             | ADSCs stimulated the generation of FoxP3 protein-expressing Treg cells, with the capacity to suppress collagen-specific T-cell responses from patients with RA | 22 (RA, PBMC)     | [81]      |

ADSC-based therapy has been reported to be efficacious, with great applicability in regenerative medicine. IPFP-MSCs, which can be easily extracted during orthopedic surgery, can resist inflammation and senescence, making them one of the best options for RA treatment. In addition, compared to bone-marrow–derived MSCs (BMSCs) and synovial MSCs, IPFP-MSCs possess a greater chondrogenic capacity with a unique age-dependent capacity for proliferation [82,83]. IPFP-MSCs have potential for ADSC-based RA treatment. Among all adult stem cells, SC-MSCs and BMSCs have identical properties [84] and are relatively accessible and abundant. ADSCs also represent a potential alternative for MSCs in many therapeutic applications. The phenotype of an ADSC-Exo is similar to that of its parent MSC. In addition, ADSCs can provide more Exos than BMSCs or synovium stem cells. Adipose-cell-free Exos do not contain cells; thus, they cannot actively contribute to tumorigenesis, and they can be used for allogeneic transplantation. In addition, ADSC-Exos are easy to carry, transport, and store, with broad therapeutic potential [85]. ADSCs secrete several cytokines, growth factors, and antioxidant factors into their microenvironments and, thus, regulate the intracellular signaling pathways in the neighboring cells [86]. For the development of adipose-cell-free Exo-based RA therapy, the factors secreted from ADSCs and the ability to collect the abundant Exos are in high demand as a new treatment strategy. Several adipose-cell-free strategies for immunomodulation in RA are currently being explored. ADSCs are abundant and can be easily collected through liposuction with minimal donor morbidity. In addition, compared to MSCs, allogeneic ADSCs exhibit improved anti-inflammatory capacity against RA because of the stronger genetic association of ADSCs with RA susceptibility and environmental risks. Until 2015, similar numbers of trials focused on allogeneic and autologous MSCs; however, more recent trials have focused on allogeneic MSCs rather than on autologous MSCs [87]. In particular, this trend indicates that future clinical trials in patients with autoimmune diseases may increasingly use allogeneic MSCs from cell banks established by private companies. Therefore, allogeneic MSC-Exos from non-RA donors may be useful for immunomodulation in synovial cells and, in turn, in the neighboring cells, thus promoting the resolution of arthritis. This approach represents a potential next-generation therapeutic strategy for RA.
3.2. Preclinical Studies on ADSCs in Animal Models

ADSCs have anti-inflammatory and regenerative properties. Several preclinical animal studies have investigated the effects of ADSCs in a mouse RA model and have identified the suppression of immune responses in vitro.

Ueyama et al. demonstrated that the localized injection of ADSCs and spheroids alleviated intra-articular inflammation and regenerated damaged cartilage in SKG mice with laminarin-induced arthritis. The authors also demonstrated the inhibitory effects of ADSCs and spheroids on synovial fibroblasts and activated macrophages through the elevation of TSG6 and TGFβ1 expression in vitro [23]. Moreover, metabolically engineered stem-cell-derived Exos systemically administered to mice with collagen-induced arthritis effectively accumulated in the inflamed joints and induced the anti-inflammatory activity through regulating macrophage phenotypes. In addition, the engineered Exos showed therapeutic efficacy equivalent to that of naked Exos at a 10-times-lower dose [88].

Gonzalez-Rey et al. reported that ADSCs stimulated the generation of FoxP3-expressing Treg cells, with the capacity to suppress collagen-specific T-cell responses. Finally, ADSCs downregulated the inflammatory responses and matrix-degrading enzyme production of synovial cells isolated from RA patients. The authors identified ADSCs as critical regulators of immune tolerance that can suppress T-cell and inflammatory responses and induce antigen-specific Treg-cell generation and activation [81]. Table 3 shows the potential of ADSCs and ADSC-Exos for alleviating the RA-related inflammation noted in preclinical animal studies.

Table 3. Potential of ADSCs and ADSC-Exos for the alleviation of the RA-related inflammation noted in preclinical animal studies.

| Preclinical Animal Study | Cell Source | Treatment Conditions | Outcome | Animal Model/Species | Reference |
|-------------------------|-------------|----------------------|---------|----------------------|----------|
|                         | Autologous subcutaneous adipose tissue | 1.5 × 10⁵ ADSCs/knee, intra-articularly | Localized injection of ADSCs and spheroids reduced intra-articular inflammation and regenerated damaged cartilage in a mouse model of RA | Laminarin-induced arthritis/ SKG mice | [23] |
| ADSC-Exos               | Human ADSC cell line | 10⁷–10⁹ dibenzocyclooctyne (DBCO)-conjugated dextran sulfate (D5)-conjugated ADSC-Exos, i.v. | D5-Exos systemically administered to mice with collagen-induced arthritis effectively accumulated in the inflamed joints, inducing a cascade of anti-inflammatory activity via regulation of macrophage phenotypes | Collagen-induced arthritis/ DBA-1J mice | [88] |
|                         | Subcutaneous adipose tissue | 5 mg EVs or 1 × 10⁶ ADSCs, i.v. | ADSC-Exos alleviated RA via transfer of factors such as IL-1ra | Collagen-induced arthritis/ BALB/c mice | [89] |
|                         | Subcutaneous adipose tissue | Exos extracted from normal MSCs with overexpressed miR-146a and miR-155 | Treatment with MSC-Exos and miR-146a/miR-155-transduced MSC-Exos significantly altered CIA mice’s Treg-cell levels and suppressed inflammation | Collagen-induced arthritis/ DBA-1J mice | [90] |

ADSC, adipose-derived stem cell; Exo, exosome; RASF, RA synovial fluid; Treg, regulatory T cell; PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin; IPFP-MSC, infrapatellar fat pad MSC; SC-MSC, subcutaneous MSC; s.c., subcutaneously; i.v., intravenously.

4. Suppression of Joint Inflammation by MSC-Exos

4.1. Characteristics of MSC-Exos

MSCs, the cell type most studied in regenerative medicine, play a major role in tissue repair and generate local anti-inflammatory and tissue-healing signals [91,92]. MSCs elicit paracrine effects through extracellular vesicles (EVs). MSC-derived EVs, particularly Exos, have prominent therapeutic roles in disease-related tissue damage or inflammation.

Exos, which are 40–150 nm EVs formed by the fusion of multivesicular cell membranes, facilitate intercellular communication through the exchange of proteins, lipids, and RNA between cells [93]. Most Exos have a conserved set of proteins, including tetraspanins (CD81, CD63, and CD9), heat-shock proteins (HSP60, HSP70, and HSP90), the ALIX protein, and the protein encoded by tumor susceptibility gene 101 (TSG101); however, they also
have unique tissue-type-specific proteins, which can reflect their cellular sources [94]. The characteristics of secreted Exos vary depending on their parent cells’ origin, type, and condition [95]. Phenotypically, MSC-derived EVs can express the MSC markers CD73, CD90, and CD105, but not CD14, CD34, or CD11b [96]. The functions of MSC-EVs are similar to those of their parent MSCs; however, the parent MSCs are more stable and safe and are less toxic, and they can more easily pass through the blood–brain barrier [97]. MSC-EVs transfer nucleic acids, lipids, proteins, and surface receptors from donor cells to specific recipient cells, thereby protecting signaling molecules from enzymatic degradation during transport [98]. MSC-EVs fuse with the recipient cell membranes by directly fusing with the plasma membranes, by fusing with the endosomal membrane after endocytosis, or by directly binding to the receptors of the recipient cells [99].

Similar to MSCs, MSC-Exos have anti-inflammatory and tissue-repairing effects, leading to a meaningful impact in RA treatment. MSC-Exos can also regulate RA symptoms through miRNAs and can reduce macrophage [88] and T- and B-cell [100] infiltration into RA cartilage. Therefore, MSC-Exos have various applications in regenerative medicine, including in immunomodulation [101] and cartilage repair [102]. They can be used as an alternative for cell-based therapy to maintain the characteristics of the original cells. The studies on the use of Exos in disease diagnosis and treatment to date have provided an essential basis for their future application in medicine.

4.2. ADSC-Exo Isolation and Identification

In RA therapy, MSC-Exos have more therapeutic potential than MSCs. First, allogeneic MSCs from patients with RA may have limited anti-inflammatory potential because of the intrinsic genetic and environmental risk factors. Therefore, whether autogenous MSC-EVs from patients with RA may secrete many other signaling molecules and trigger other diseases warrants further investigation. Second, MSCs may lead to tumor formation. Therefore, MSC-Exos are more effective, less toxic, and more stable than their parent cells [103]. Allogeneic MSC-Exos are regulated by specific pathways underlying RA symptoms. In addition, allogeneic MSC-Exos transfer various nucleic acids, proteins, and lipids from their parent cells to the recipient cells and thus participate in the inhibition of RA progression. Notably, similar methods can be used for the isolation and characterization of Exos from different MSCs. In general, isolated Exos can be examined using transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), resistive pulse sensing, and microfluidics and electrochemical biosensors [104,105]. MSC-Exos contain general markers, cell-surface markers (CD9, CD63, and CD81), transport proteins (annexins and flotillin), a heat-shock protein (HSP70), endosomal sorting complexes required for transport (ESCRT complex; TSG101, ALIX, and phospholipases), and other lipid-related proteins [106,107].

One of the most common methods used for Exo purification is differential ultracentrifugation (UC). In addition, an Exo precipitation–isolation method, which can be performed using a commercial Exo isolation kit, is commonly used. Tangential flow filtration (TFF) is another emerging technology that couples permeable membrane filtration and flow to obtain an efficient Exo concentration in a colloidal matrix. A comparative assessment of TFF and UC for a conditioned cell culture medium revealed that TFF aids in concentrating EVs with comparable physicochemical characteristics, with a high yield, few single macromolecules, and aggregates (size < 15 nm), and improved batch-to-batch consistency in half the processing time (1 h). Thus, Exos from adipose tissues are of high clinical relevance because they are expected to mimic the regenerative properties of their parent MSC cells. Most relevant clinical studies have used different Exo preparation methods and have thus reported inconsistent results. Heterogeneous MSCs from patients with heterogenous RA demonstrate considerably diverse immunomodulatory and differentiation functions. Therefore, the types of molecules assembled by the extracted Exos may be heterogenous and may show altered functions in recipient cells, thus eliciting changes in the physiological processes. Moreover, miRNAs do not enter MSC-EVs equally. Finally, MSC-Exo separation
methods have not been standardized to date. Even when commercial Exo extractants are used, the resulting Exos may contain non-Exo contaminants, such as lipoproteins, warranting the further purification of said Exos [103]. Therefore, the findings presented here should be replicated in large-scale clinical trials to assess the safety, effectiveness, and persistence of allogeneic MSC-Exos in patients with RA.

4.3. MSCs and MSC-Exos in Animal Models

MSCs mainly interact with both innate and adaptive immune cells to modulate immune responses in patients with RA. MSC-based therapy is currently administered to patients with RA unresponsive to conventional RA therapy, and it is not associated with serious adverse events. Although several clinical trials have reported the effects of MSC-based therapy in patients with RA, no optimal MSC-based therapeutic protocol for patients with RA has been proposed [108]. Therefore, the use of MSCs in RA treatment is challenging. Most studies have used allogenic MSCs, because isolating and propagating a sufficient number of autologous MSCs from patients with RA can be difficult. Autologous MSCs from patients with RA may have intrinsic genetic defects that may impair their anti-inflammatory capacity. Notably, patients with RA require long-term treatment to control symptoms and prevent structural damage, which may hamper MSCs’ function.

Accumulating evidence suggests that MSC-Exos efficiently transfer small-molecule drugs or proteins to target cells. However, MSC-Exos have not been applied to RA treatment. Nevertheless, the effectiveness of MSC-Exo-based therapy has been established in experimental animal models of RA, where MSC-Exo-based therapy has been noted to significantly alleviate the induction and progression of experimental arthritis. Of these models, the collagen-induced arthritis (CIA) mouse model is most widely used for assessing the efficacy of MSC-Exo-based therapy. Other studies have shown that MSC-Exos can suppress inflammation more effectively in RA than can MSC-derived microparticles [100]. MSC-Exos were noted to suppress T-cell proliferation in a dose-dependent manner and lower the numbers of mature T- and B-cell subsets [100,109,110]. Exos more effectively enhanced the population of Treg cells than did MSCs [110] and MSC-derived microvesicles [100]. However, some studies have demonstrated that microvesicles derived from MSCs are less effective in inducing TGFβ and IL-10 production in B and T cells than are MSCs alone [111]. Li et al. reported that, in CIA mice, MSC-derived miRNA-150-5p-expressing Exos reduce the secretion of inflammatory cytokines, including TNF-α and IL-1β, suppressing RA progression in vivo [112]. Moreover, miR-146a-transduced MSC-Exos were found to increase FoxP3 (a transcriptional factor expressed in Treg cells), TGFβ, and IL10 expression in CIA mice [90]. MSC-derived exosomal circFBXW7 suppressed the proliferation, migration, and inflammatory responses of rheumatoid fibroblast-like synoviocytes and alleviated RA in rats by sponging miR-216a-3p and activating HDAC4 [113].

Studies have also shown that targeted alterations of gene expression in Exos can alleviate RA by enhancing the Exos’ anti-inflammatory capacity. Tsujimaru et al. demonstrated that ADSC-Exos were themselves involved in RA-amelioration mechanisms by examining the functional effects of ADSC-Exos in RA development. Moreover, in mice, wild-type ADSCs and ADSC-Exos alleviated joint inflammation more significantly than did IL-1ra−/− mouse ADSC-Exos [89]. These promising results have paved the way for MSC-Exo-based therapy to become a favorable new treatment modality for RA in humans.

Exo-transfected miRNAs could alleviate inflammation in mice with RA. Tavasolian et al. reported that, in mice with CIA, miR-146a-transduced ADSC-Exos increased FoxP3, TGFβ, and IL10 expression, whereas miR-155-transduced ADSC-Exos increased RORγt, IL17, and IL6 expression. Therefore, Exos can act as vehicles for the intracellular transfer of miRNAs between cells and represent a possible therapeutic strategy for RA [90]. Other in vitro studies showed increased target miRNAs in Exos derived from bone marrow stem cells, inhibiting inflammation in mice with RA; these miRNAs included miR-150-5p, miR-548e, miR-34a, miR-320a, miR-124a, miR-216a-3p, miR-192-5p, and miR-143-3p [111,113–119].
Figure 3 illustrates the currently available therapies for RA, including cell and non-cell therapies. To date, human studies on the effects of ADSCs on RA have been limited by small sample sizes, a lack of objective indices for response evaluation, and short follow-up durations [24,77,78]. Therefore, the interpretation of the anti-inflammatory potential of autogenous ADSCs is difficult. Many recent studies have demonstrated that non-cell Exos can be stable and effective vehicles for specific proteins, lipids, and genetic materials, including mRNAs, miRNAs, other small noncoding RNAs, and DNA; therefore, they may be promising tools for drug delivery to target tissues or organs [120]. MSC-Exo miRNAs regulate many physiological processes at the transcriptional and posttranscriptional levels. Chen et al. reported that miR-150-5p-overexpressing MSC-Exos reduced joint destruction by inhibiting the hyperplasia of synoviocytes and angiogenesis in patients with RA. miRNA-carrying MSC-Exos may be a new strategy for stem-cell-derived drug and miRNA delivery in patients with RA [111].

4.4. Biomaterial and Clinical Applications of ADSC-Exos

In addition, although clinical-grade Exos can be produced using biomaterials and standard operating procedures, methods for the large-scale production of Exos for clinical use have not been reported. Nevertheless, valuable biomaterials can be used to maximize the therapeutic power of ADSC-Exos. Consequently, hydrogels have attracted considerable attention as biocompatible auxiliary materials in recent years [121].

In the RA experimental models, using an injectable hydrogel prolonged the retention time for the MSC-Exos, enhancing their therapeutic effect. The route and dose of Exo administration must thus be explored to ensure the safety of patients treated with ADSC-Exos. The primary administration route used in preclinical animal studies has been intra-articular. Therefore, the most appropriate route of Exo administration in RA patients in the clinic warrants investigation.

The methods for coating Exos on nanoparticle surfaces are similar to those for coating them on cell membranes. To date, most nanoparticles coated with Exos have been metallic, including gold nanoparticles, iron oxide nanoparticles (IONs), and gold-IONs. However,
in some cases, poly(lactic-co-glycolic acid) nanoparticles and metal–organic framework nanoparticles have been coated with Exos. Exo-based nanoparticle coatings enable the expansion of nanoparticle targeting from typical approaches that target individual antigens to a strategy that can simultaneously target many antigens for more efficient uptake by target cells. In addition, Exo-derived coatings have immune-evasive properties that can increase the retention times [122]. Clinical trials monitoring patients treated with ADSC-Exos in real time are required to determine the effectiveness of ADSC-Exos at low doses. Therefore, future breakthrough research should combine basic research on ADSC-Exos with other emerging biomaterials for RA treatment.

5. Conclusions

RA treatment is challenging. In some patients with RA, the currently available treatment modalities cannot completely alleviate RA symptoms. In this review, we discussed the immunomodulatory effects of ADSCs and ADSC-Exos on immune cells, as well as RA progression under ADSC-Exo-based treatment; in general, ADSC-Exos may represent novel therapeutic agents for the cell-free or cell-component-based treatment of RA. Despite the encouraging results, denoted by target gene or miRNA overexpression, the clinical potential of ADSC-Exos as drug vectors in an appropriate form for administration warrants further analysis.

Author Contributions: Conceptualization, H.-J.L., C.-H.C. and T.-H.C.; investigation, H.-J.L. and T.-H.C.; writing—original draft preparation, H.-J.L.; writing—review and editing, H.-J.L., C.-H.C. and T.-H.C.; supervision, S.-H.C., C.-S.W. and C.-H.C.; project administration, H.-J.L., C.-H.C. and T.-H.C.; funding acquisition, H.-J.L. and C.-H.C. All authors have read and agreed to the published version of the manuscript.

Funding: Ministry of Science and Technology (108-2314-B-418-010-MY3, 109-2314-B-239-001-MY3, 109-2923-M-010-001-MY3, and 111-2321-B-418-002-), FEMH (2022-C-042 and 2022-C-123), and NYCU-FEMH Cooperation (109DN24, 110DN22, 111DN12 and 111DN22) grants.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: There are no conflicts of interest to report.

References

1. Chemin, K.; Gerstner, C.; Malmstrom, V. Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation—Lessons from Rheumatoid Arthritis. Front. Immunol. 2019, 10, 353. [CrossRef] [PubMed]
2. Peters, M.A.; Wendholt, D.; Strietholt, S.; Frank, S.; Pundt, N.; Korb-Pap, A.; Joosten, L.A.; van den Berg, W.B.; Kollias, G.; Eckes, B.; et al. The loss of alpha2beta1 integrin suppresses joint inflammation and cartilage destruction in mouse models of rheumatoid arthritis. Arthritis Rheum. 2012, 64, 1359–1368. [CrossRef] [PubMed]
3. Bird, P.; Peterfy, C.; Countryman, P.; Griffiths, H.; Barrett, R.; Yousef, P.; Joshua, F.; Hall, S. AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis. Int. J. Rheumatol. 2018, 8721753. [CrossRef]
4. Poole, J.A.; Thiele, G.M.; Janike, K.; Nelson, A.J.; Duryee, M.J.; Rentfro, K.; England, B.R.; Romberger, D.J.; Carrington, J.M.; Wang, D.; et al. Combined Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation to Model Inflammatory Lung Disease in Rheumatoid Arthritis. J. Bone Miner. Res. 2019, 34, 1733–1743. [CrossRef] [PubMed]
5. Greisen, S.R.; Kragstrup, T.W.; Thomsen, J.S.; Hansen, A.S.; Krishnamurthy, A.; Hørslev-Petersen, K.; Hetland, M.L.; Stengaard-Pedersen, K.; Østergaard, M.; Ørnbjerg, L.M.; et al. Programmed death ligand 2—A link between inflammation and bone loss in rheumatoid arthritis. J. Transl. Autoimmun. 2020, 3, 100028. [CrossRef]
6. McInnes, I.B.; Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011, 365, 2205–2219. [CrossRef]
7. Okada, Y.; Wu, D.; Trynka, G.; Raj, T.; Terao, C.; Ikari, K.; Kochi, Y.; Ohmura, K.; Suzuki, A.; Yoshida, S.; et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014, 506, 376–381. [CrossRef]
8. Flogel, U.; Burghoff, S.; van Lent, P.L.; Temme, S.; Galbarz, L.; Ding, Z.; El-Tayeb, A.; Huels, S.; Bonner, F.; Borg, N.; et al. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci. Transl. Med. 2012, 4, 146ra108. [CrossRef]
9. Patlan, M.; Paez, A.; Masso, F.; Amezcu-a-Guerra, L.M. Relative increase of Th17 phenotype in senescent CD4+CD28null T cells from peripheral blood of patients with rheumatoid arthritis. *Clin. Exp. Rheumatol.* 2021, 39, 925–926. [CrossRef]

10. Paradowska-Gorycka, A.; Wajda, A.; Romanovska-Prochnicka, K.; Walczuk, E.; Kuca-Warna win, E.; Kmi olek, T.; S typinska, B.; Rzeszotarska, E.; Majewski, D.; Jagodziński, P.F.; et al. Th17/Treg-Related Transcriptional Factor Expression and Cytokine Profile in Patients With Rheumatoid Arthritis. *Front. Immunol.* 2020, 11, 572858. [CrossRef]

11. Van Raemdonck, K.; Umar, S.; Palasievič, V.; Volkov, S.; Volin, M.V.; Arami, S.; Chang, H.J.; Zanotti, B.; Schweis, N.; Shahrra, S. CCL21/CCR7 signaling in macrophages promotes joint inflammation and Th17-mediated osteoclast formation in rheumatoid arthritis. *Cell. Mol. Life Sci.* 2020, 77, 1387–1399. [CrossRef] [PubMed]

12. Park, J.S.; Kwok, S.K.; Lim, M.A.; Kim, E.K.; Ryu, J.G.; Kim, S.M.; Oh, H.J.; Ju, J.H.; Park, S.H.; Kim, H.Y.; et al. STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis. *Arthritis Rheumatol.* 2014, 66, 918–929. [CrossRef] [PubMed]

13. Rao, D.A.; Gurish, M.F.; Marshall, J.L.; Slowikowski, K.; Fonseka, C.Y.; Liu, Y.; Donlin, L.T.; Henderson, L.A.; Wei, K.; Mizoguchi, F.; et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. *Nature* 2017, 542, 110–114. [CrossRef] [PubMed]

14. Gomez, E.A.; Colas, R.A.; Souza, P.R.; Hands, R.; Lewis, M.J.; Bessant, C.; Pitzalis, C.; Dalli, J. Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis. *Nat. Commun.* 2020, 11, 5420. [CrossRef]

15. Khadem Azarian, S.; Jafarnezhad-Ansariha, F.; Nazeri, S.; Azizi, G.; Aghazadeh, Z.; Hosseinzadeh, E.; Mirshafiey, A. Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORgammat, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients. *Immunopharmacol. Immunotoxicol.* 2020, 42, 22–27. [CrossRef]

16. Movahedi, M.; Costello, R.; Lunt, M.; Pye, S.R.; Sergeant, J.C.; Dixon, W.G. Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: A retrospective cohort study. *Eur. J. Epidemiol.* 2016, 31, 1045–1055. [CrossRef] [PubMed]

17. Lauper, K.; Mongin, D.; Alpizar-Rodriguez, D.; Codreanu, C.; Iannone, F.; Kristianslund, E.K.; Pavelka, K.; Pombo-Suarez, M.; Santos, M.J.; et al. Drug retention of biological DMARD in rheumatoid arthritis patients: The role of baseline characteristics and disease evolution. *Rheumatology* 2019, 58, 2221–2229. [CrossRef]

18. Harrington, R.; Al Nokhatha, S.A.; Conway, R. JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data. *J. Inflamm. Res.* 2020, 13, 519–531. [CrossRef]

19. Tweehuysen, L.; den Broeder, A.A.; Schraa, K.; Netea, M.G.; van den Hoogen, F.H.J.; Joosten, L.A.B. Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. *Clin. Exp. Rheumatol.* 2019, 37, 367–372.

20. Wilke, T.; Mueller, S.; Lee, S.C.; Majer, I.; Heisen, M. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: A retrospective non-interventional cohort analysis. *BMC Musculoskelet. Disord.* 2017, 18, 332. [CrossRef]

21. Ceccarelli, S.; Pontecorvi, P.; Anastasiadou, E.; Napoli, C.; Marchese, C. Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application. *Front. Cell Dev. Biol.* 2020, 8, 236. [CrossRef] [PubMed]

22. Jang, S.G.; Lee, J.; Hong, S.M.; Kwok, S.K.; Cho, M.L.; Park, S.H. Metformin enhances the immunomodulatory potential of adipose-derived mesenchymal stem cells through STAT1 in an animal model of lupus. *Rheumatology* 2020, 59, 1426–1438. [CrossRef] [PubMed]

23. Ueyama, H.; Okano, T.; Orita, K.; Mamoto, K.; Sobajima, S.; Iwaguro, H.; Nakamura, H. Local transplantation of adipose-derived mesenchymal stem cells has a significant therapeutic effect in a mouse model of rheumatoid arthritis. *Sci. Rep.* 2016, 6, 22814. [CrossRef] [PubMed]

24. Lopez-Santalla, M.; Bueren, J.A.; Garin, M.I. Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies. *EBioMedicine* 2021, 69, 103427. [CrossRef]

25. Mallinson, D.J.; Dunbar, D.R.; Ridha, S.; Sutton, E.R.; De la Rosa, O.; Dalemans, W.; Lombardo, E. Identification of Potential Plasma microRNA Stratification Biomarkers for Response to Allogeneic Adipose-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis. *Stem. Cells Transl. Med.* 2017, 6, 1202–1206. [CrossRef] [PubMed]

26. Skalska, U.; Kontny, E. Adipose-derived mesenchymal stem cells from infrapatellar fat pad of patients with rheumatoid arthritis and osteoarthritis have comparable immunomodulatory properties. *Autoimmunity* 2016, 49, 124–131. [CrossRef] [PubMed]

27. Debroevoa, M.; Culenova, M.; Smolinska, V.; Nicodemou, A.; Csoybonyeiwoa, M.; Danisovic, L. Rheumatoid arthritis: From synovium biology to cell-based therapy. *Cytotheraphy* 2022, 24, 365–375. [CrossRef]

28. Crossfield, S.S.R.; Buch, M.H.; Baxter, P.; Kingsbury, S.R.; Pujades-Rodriguez, M.; Conaghan, P.G. Changes in the pharmacological management of rheumatoid arthritis over two decades. *Rheumatology* 2021, 60, 4141–4151. [CrossRef]

29. Ahiwula, V.; Rampakakis, E.; Movahedi, M.; Cesta, A.; Li, X.; Sampalis, J.S.; Bombardier, C. Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: Results from the Ontario best practices research initiative. *Clin. Rheumatol.* 2017, 36, 2421–2430. [CrossRef]

30. Rosales Rosado, Z.; Font Urgelles, J.; Hernandez Rodriguez, I.; Leon Mateos, L.; Abasolo Alcazar, L.; Jover Jover, J.A. Clinical management and discontinuation of treatment in patients with recent onset rheumatoid arthritis in a rheumatology consultation. *Rheumatol. Clin. (Engl. Ed.)* 2022, 18, 77–83. [CrossRef]
31. Fletcher, A.; Lassere, M.; March, L.; Hill, C.; Barrett, C.; Carroll, G.; Buchbinder, R. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis. *Rheumatology* 2022. [CrossRef]

32. Tanaka, Y. Recent progress in treatments of rheumatoid arthritis: An overview of developments in biologics and small molecules, and remaining unmet needs. *Rheumatology* 2021, 60, v112–v120. [CrossRef]

33. Nakayamada, S.; Kubo, S.; Iwata, S.; Tanaka, Y. Chemical JAK inhibitors for the treatment of rheumatoid arthritis. *Expert Opin. Pharmacother.* 2016, 17, 2215–2225. [CrossRef]

34. Chen, Y.F.; Jobanputra, P.; Barton, P.; Bryan, S.; Fry-Smith, A.; Harris, G.; Taylor, R.S. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: A systematic review and economic evaluation. *Health Technol. Assess.* 2008, 12, 1–278. [CrossRef]

35. Bickham, K.; Kivitz, A.J.; Mehta, A.; Frontera, N.; Shah, S.; Stryszak, P.; Popmihajlov, Z.; Peloso, P.M. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. *BMC Musculoskelet. Disord.* 2016, 17, 331. [CrossRef]

36. Moller, B.; Pruijm, M.; Adler, S.; Scherer, A.; Villiger, P.M.; Finckh, A.; Swiss Clinical Quality Management in Rheumatic Diseases Foundation, C.H.Z.S. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. *Ann. Rheum. Dis.* 2015, 74, 718–723. [CrossRef]

37. Sullivan, F.; Rasool, M. A novel therapeutic approach targeting rheumatoid arthritis by combined administration of morin, a dietary flavonol and non-steroidal anti-inflammatory drug indomethacin with reference to pro-inflammatory cytokines, inflammatory enzymes, RANKL and transcription factors. *Chem. Biol. Interact.* 2015, 230, 58–70. [CrossRef]

38. Tacheci, I.; Branda, P.; Douda, T.; Bastecka, D.; Kopacova, M.; Rejchrt, S.; Bures, J. NSAID-Induced Enteropathy in Rheumatoid Arthritis Patients with Chronic Occult Gastrointestinal Bleeding: A Prospective Capsule Endoscopy Study. *Gastroenterol. Res. Pract.* 2013, 2013, 268382. [CrossRef]

39. Crilly, M.A.; Mangoni, A.A. Non-steroidal anti-inflammatory drug (NSAID) related inhibition of aldosterone glucuronidation and arterial dysfunction in patients with rheumatoid arthritis: A cross-sectional clinical study. *BMJ Open* 2011, 1, e000076. [CrossRef]

40. Pazmino, S.; Boonen, A.; De Cock, D.; Stouten, V.; Joly, J.; Bertrand, D.; Westhovens, R.; Verschueren, P. Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: Subanalysis of the CareRA randomised controlled trial. *RMD Open* 2021, 7, e001615. [CrossRef]

41. Strehl, C.; van der Goes, M.C.; Bijlsma, J.W.; Jacobs, J.W.; Buttgereit, F. Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis. *Expert Opin. Investig. Drugs* 2017, 26, 187–195. [CrossRef] [PubMed]

42. Bijlsma, J.W. Disease control with glucocorticoid therapy in rheumatoid arthritis. *Rheumatology* 2012, 51 (Suppl. S4), iv9–iv13. [CrossRef]

43. Palmowski, A.; Nielsen, S.M.; Buttgereit, T.; Palmowski, Y.; Boers, M.; Christensen, R.; Buttgereit, F. Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. *Semin. Arthritis Rheum.* 2020, 50, 1400–1405. [CrossRef]

44. Kvien, T.K.; Greenwald, M.; Peloso, P.M.; Wang, H.; Mehta, A.; Gammaitoni, A. Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. *BMC Musculoskelet. Disord.* 2015, 16, 26. [CrossRef]

45. Stouten, V.; Westhovens, R.; Pazmino, S.; De Cock, D.; Van der Elst, K.; Joly, J.; Verschueren, P.; Care, R.A.s.g. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: Two-year results of CareRA. *Rheumatology* 2019, 58, 2284–2294. [CrossRef]

46. Strehl, C.; van der Goes, M.C.; Bijlsma, J.W.; Jacobs, J.W.; Buttgereit, F. Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis. *Expert Opin. Investig. Drugs* 2017, 26, 187–195. [CrossRef] [PubMed]

47. Gossye, V.; Elewaut, D.; Bougarne, N.; Bracke, D.; Van Calenbergh, S.; Haegeman, G.; De Bosscher, K. Differential mechanism of NF-kappaB inhibition by two glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts. *Arthritis Rheum.* 2009, 60, 3241–3250. [CrossRef]

48. Guo, Q.; Wang, Y.; Xu, D.; Nossent, J.; Pavlos, N.J.; Xu, J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. *Bone Res.* 2018, 6, 15. [CrossRef]

49. Wang, W.; Zhou, H.; Liu, L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. *Eur. J. Med. Chem.* 2018, 158, 502–516. [CrossRef]

50. Dimitrova, P.; Kalden, J.R.; Schulze-Koops, H. Leflunomide: An immunosuppressive drug with multiple effects on T cell function. *Mod. Rheumatol.* 2002, 12, 195–200. [CrossRef]

51. Meier, F.M.; Freix, M.; Hermann, W.; Muller-Ladner, U. Current immunotherapy in rheumatoid arthritis. *Immunotherapy* 2013, 5, 955–974. [CrossRef] [PubMed]

52. Shams, S.; Martinez, J.M.; Dawson, J.R.D.; Flores, J.; Gabriel, G.; Guevara, A.; Murray, K.; Pacífico, N.; Vargas, M.V.; et al. The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. *Front. Pharmacol.* 2021, 12, 68043. [CrossRef] [PubMed]

53. Klarenbeek, N.B.; Kerstens, P.J.; Huizinga, T.W.; Dijkmans, B.A.; Allaart, C.F. Recent advances in the management of rheumatoid arthritis. *BMJ* 2010, 341, c6942. [CrossRef]
54. Bai, L.L.; Chen, H.; Zhou, P.; Yu, J. Identification of Tumor Necrosis Factor-Alpha (TNF-alpha) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking. *Front. Pharmacol.* 2021, 12, 690118. [CrossRef]

55. Carvalhal Alegria, G.; Cornejo, D.; Saura, A.; Devauchelle-Pensec, V.; Jamin, C.; Hillion, S.; Pers, J.O.; Pochard, P. Abatacept Promotes Regulatory B Cell Functions, Enhancing Their Ability to Reduce the Th1 Response in Rheumatoid Arthritis Patients through the Production of IL-10 and TGF-beta. *J. Immunol.* 2021, 207, 470–482. [CrossRef]

56. Cacciapaglia, F.; Renna, D.; Fornaro, M.; Venerito, V.; Lopalco, G.; Iannone, F. Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: Real world experience from a single Italian rheumatology centre. *Clin. Exp. Rheumatol.* 2021, 39, 1147–1148. [CrossRef]

57. Saki, A.; Rajaei, E.; Rahim, F. Safety and efficacy of tocilizumab for rheumatoid arthritis: A systematic review and meta-analysis of clinical trial studies. *Reumatologija* 2021, 59, 169–179. [CrossRef]

58. Holdsworth, E.A.; Donaghy, B.; Fox, K.M.; Desai, P.; Collier, D.H.; Furst, D.E. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis. *Rheumatol. Ther.* 2021, 8, 1637–1649.

59. de Launay, D.; van de Sande, M.G.; de Hair, M.J.; Grabiec, A.M.; van de Sande, G.P.; Lehmann, K.A.; Wijbrandts, C.A.; van Baaren, L.G.; Gerlag, D.M.; Tak, P.P.; et al. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): A prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. *Ann. Rheum. Dis.* 2012, 71, 415–423. [CrossRef]

60. Song, X.; Zhang, Y.; Dai, E.; Du, H.; Wang, L. Mechanism of action of celestrol against rheumatoid arthritis: A network pharmacology analysis. *Int. Immunopharmacol.* 2019, 74, 105725. [CrossRef]

61. Singh, J.A.; Saag, K.G.; Murphy, K.P.; Su, X.;紧; Vasquez, S.; McNaughton, C.; Osani, M.; Shmerling, R.H.; et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res.* 2016, 68, 1–25. [CrossRef]

62. Senolt, L.; Vencovsky, J.; Pavelka, K.; Ospelt, C.; Gay, S. Prospective new biological therapies for rheumatoid arthritis. *Autoimmun. Rev.* 2009, 9, 102–107. [CrossRef] [PubMed]

63. Bonilla-Hernan, M.G.; Miranda-Carus, M.E.; Martin-Mola, E. New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors. *Rheumatology* 2011, 50, 1542–1550. [CrossRef] [PubMed]

64. Sarsenova, M.; Issabekova, A.; Abisheva, S.; Rutskaya-Moroshan, K.; Ogay, V.; Saparov, A. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. *Int. J. Mol. Sci.* 2021, 22, 1992. [CrossRef]

65. Haikal, S.M.; Abdeltawab, N.F.; Rashed, L.A.; Abd El-Galil, T.I.; Elmalt, H.A.; Amin, M.A. Combination Therapy of Mesenchymal Stromal Cells and Interleukin-4 Attenuates Rheumatoid Arthritis in a Collagen-Induced Murine Model. *Cells* 2019, 8, 823. [CrossRef]

66. El-Jawhari, J.J.; El-Sherbiny, Y.; McGonagle, D.; Jones, E. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus: From a Leading Role in Pathogenesis to Potential Therapeutic Saviors? *Front. Immunol.* 2021, 12, 643170. [CrossRef]

67. Ansboro, S.; Roelofs, A.J.; De Bari, C. Mesenchymal stem cells for the management of rheumatoid arthritis: Immune modulation, repair or both? *Curr. Opin. Rheumatol.* 2017, 29, 201–207. [CrossRef]

68. Jiang, Q.; Yang, G.; Liu, Q.; Wang, S.; Cui, D. Function and Role of Regulatory T Cells in Rheumatoid Arthritis. *Front. Immunol.* 2021, 12, 626193. [CrossRef]

69. Tanaka, Y. Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. *Clin. Exp. Rheumatol.* 2015, 33, S58–S62.

70. Pedrosa, M.; Gomes, J.; Laranjeira, P.; Duarte, C.; Pedreiro, S.; Martinho, A.; Fardilha, M.; et al. Immunomodulatory effect of human bone marrow-derived mesenchymal stromal/stem cells on peripheral blood T cells from rheumatoid arthritis patients. *J. Tissue Eng. Regen. Med.* 2020, 14, 16–28. [CrossRef]

71. Shalev-Malul, G.; Soler, D.C.; Ting, A.E.; Lehman, N.A.; Barnbyom, E.; McCormick, T.S.; Anthony, D.D.; Lazarus, H.M.; Caplan, A.L.; Breitman, M.; et al. Development of a Functional Biomarker for Use in Cell-Based Therapy Studies in Seropositive Rheumatoid Arthritis. *Stem Cells Transl. Med.* 2016, 5, 628–631. [CrossRef]

72. Dallos, T.; Krivosikova, M.; Chorazy-Massalska, M.; Warnawin, E.; Zanova, E.; Rudnicka, W.; Radzikowska, A.; Maslinski, W. BAFF from bone marrow-derived mesenchymal stromal cells of rheumatoid arthritis patients improves their B-cell viability-supporting properties. *Folia Biol.* 2009, 55, 166–176.

73. Skalska, U.; Chrobok, S.; Kontny, E. Osteoelastic potential of infrapatellar fat pad-derived mesenchymal stem cells from rheumatoid arthritis patients. *Int. J. Rheum. Dis.* 2016, 19, 577–585. [CrossRef] [PubMed]

74. Skalska, U.; Kuca-Warnawin, E.; Kornatka, A.; Janicka, I.; Musialowicz, U.; Burakowski, T.; Kontny, E. Articular and subcutaneous adipose tissues of rheumatoid arthritis patients represent equal sources of immunoregulatory mesenchymal stem cells. *Autoimmunity* 2017, 50, 441–450. [CrossRef]

75. Alvaro-Gracia, J.M.; Jover, J.A.; Garcia-Vicuna, R.; Carreno, L.; Alonso, A.; Marsal, S.; Blanco, F.; Martinez-Taboada, V.M.; Taylor, P.; Martin-Martin, C.; et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. *Ann. Rheum. Dis.* 2017, 76, 196–202. [CrossRef]
100. Cosenza, S.; Toupet, K.; Maumus, M.; Luz-Crawford, P.; Blanc-Brude, O.; Jorgensen, C.; Noel, D. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. *Theranostics* 2018, 8, 1399–1410. [CrossRef]

101. Dabrowska, S.; Andrzejewska, A.; Janowski, M.; Lukomska, B. Immunomodulatory and Regenerative Effects of Mesenchymal Stem Cells and Extracellular Vesicles: Therapeutic Outlook for Inflammatory and Degenerative Diseases. *Front. Immunol.* 2020, 11, 591065. [CrossRef] [PubMed]

102. Wu, J.; Kuang, L.; Chen, C.; Yang, J.; Zeng, W.N.; Li, T.; Chen, H.; Huang, S.; Fu, Z.; Li, J.; et al. miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis. *Biomaterials* 2019, 206, 87–100. [CrossRef] [PubMed]

103. Liu, H.; Li, R.; Liu, T.; Yang, L.; Yin, G.; Xie, Q. Immunomodulatory Effects of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Rheumatoid Arthritis. *Front. Immunol.* 2020, 11, 1912. [CrossRef] [PubMed]

104. Thery, C.; Amigorena, S.; Raposo, G.; Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr. Protoc. Cell Biol.* 2006, 30, 3–22. [CrossRef] [PubMed]

105. Dragovic, R.A.; Gardiner, C.; Brooks, A.S.; Tannetta, D.S.; Ferguson, D.J.; Hole, P.; Carr, B.; Redman, C.W.; Harris, A.L.; Dobson, P.; et al. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. *Biomedicine* 2011, 7, 780–788. [CrossRef]

106. Vickers, K.C.; Remaley, A.T. Lipid-based carriers of microRNAs and intercellular communication. *Curr. Opin. Lipidol.* 2012, 23, 91–97. [CrossRef]

107. Thery, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. *Nat. Rev. Immunol.* 2009, 9, 581–593. [CrossRef]

108. Lopez-Santalla, M.; Fernandez-Perez, R.; Garin, M.I. Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications. *Cells* 2020, 9, 1852. [CrossRef]

109. Tian, J.; Zhu, Q.; Zhang, Y.; Bian, Q.; Hong, Y.; Shen, Z.; Xu, H.; Rui, K.; Yin, K.; Wang, S. Olfactory Ecto-Mesenchymal Stem Cell-Derived Exosomes Ameliorate Experimental Colitis via Modulating Th1/Th17 and Treg Cell Responses. *Front. Immunol.* 2020, 11, 598322. [CrossRef]

110. Lopez-Santalla, M.; Fernandez-Perez, R.; Garin, M.I. Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications. *Cells* 2020, 9, 1852. [CrossRef]

111. Chang, L.; Kan, L. Mesenchymal Stem Cell-Originated Exosomal Circular RNA circFBXW7 Attenuates Cell Proliferation, Migration and Inflammation of Fibroblast-Like Synoviocytes by Targeting miR-216a-3p/HDAC4 in Rheumatoid Arthritis. *J. Orthop. Surg. Res.* 2021, 16, 116. [CrossRef]

112. Zheng, J.; Zhu, L.; Iok In, I.; Chen, Y.; Jia, N.; Zhu, W. Bone marrow mesenchymal stem cell-derived extracellular vesicles targets TET1 to suppress KLF4 and alleviate rheumatoid arthritis. *Ther. Adv. Chronic Dis.* 2021, 12, 2040623211007369. [CrossRef] [PubMed]

113. Liu, G.Q.; Fang, Y.X.; Liu, Y.; Meng, F.R.; Wu, X.; Zhang, C.W.; Zhang, Y.; Liu, Y.Q.; Liu, D. MicroRNA-21 from bone marrow mesenchymal stem cell-derived extracellular vesicles targets TET1 to suppress KLF4 and alleviate rheumatoid arthritis. *Ther. Adv. Chronic Dis.* 2022, 6, 2472–2482. [CrossRef] [PubMed]

114. Su, Y.; Liu, Y.; ma, C.; Guan, C.; Ma, X.; Meng, S. Mesenchymal stem cell-originated exosomal IncRNA HAND2-AS1 impairs rheumatoid arthritis fibroblast-like synoviocyte activation through miR-143-3p/TNFAIP3/NF-kappaB pathway. *J. Immunol.* 2020, 204, 6157–6171. [CrossRef] [PubMed]

115. Meng, Q.; Qu, B. Exosomal MicroRNA-320a Derived From Mesenchymal Stem Cells Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Activation by Suppressing CXCL9 Expression. *Front. Physiol.* 2020, 11, 441. [CrossRef]

116. Meng, H.Y.; Chen, H.; Hu, X.; Wang, Y.; Luo, B.; Huang, W.; Gu, J. miR-34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I/ATM/ATR/p53 axis. *J. Cell. Mol. Med.* 2021, 25, 1896–1910. [CrossRef]

117. Yan, X.; Cen, Y.; Wang, Q. Mesenchymal stem cells alleviate experimental rheumatoid arthritis through microRNA-regulated IkappaB expression. *Sci. Rep.* 2016, 6, 28915. [CrossRef]

118. Bunggulawa, E.J.; Wang, W.; Yin, T.; Wang, N.; Durkan, C.; Wang, Y.; Wang, G. Recent advancements in the use of exosomes as drug delivery systems. *J. Nanobiotechnol.* 2018, 16, 81. [CrossRef]

119. Lenzini, S.; Bargi, R.; Chung, G.; Shin, J.W. Matrix mechanics and water permeation regulate extracellular vesicle transport. *Nat. Nanotechnol.* 2020, 15, 217–223. [CrossRef] [PubMed]

120. Holc, M.; Kanduser, M.; Lenassi, M. Blood Nanoparticles—Influence on Extracellular Vesicle Isolation and Characterization. *Front. Pharmacol.* 2021, 12, 773844. [CrossRef] [PubMed]